Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms

NCT00637884 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00637884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2003
Completion date
February 29, 2004
Enrollment
70 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cat induced allergic rhinitis